Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate

Prostate

Volumn 56, Issue 3, 2003, Pages 171-182

  Steiner, Georg E ^a   Newman, Martin E ^a   Paikl, Doris ^a   Stix, Ursula ^a   Memaran Dagda, Nima ^a   Lee, Chung ^b   Marberger, Michael J ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Department of Urology ^*  (United States)

Author keywords

Inflammation; Interleukin 17; Proinflammatory cytokines; Prostate

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; T LYMPHOCYTE ACTIVATION; TUMOR CELL LINE;

EID: 0041669594     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10238     Document Type: Article

References (57)

1. Franks LM. Benign prostatic hyperplasia: Gross and microscopic anatomy. In: Grayhack JT, Wilson JD, Scherbenske MJ, editors. Benign prostatic hyperplasia. Department of Health, Education, and Welfare (NIH) Publication. Washington DC: US Government Printing Office; 1976. p 76-1113.
2. Bartsch G, Frick J, Rüegg I, Bucher M, Holliger O, Oberholzer M, Rohr HP. Electron microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979;122:481-491.
3. Bartsch G, Rohr HP. Die Bedeutung des Stromas bei der Pathomorphogenese der menschlichen Prostatahyperplasie. Aktuel Urol 1979;10:137-143.
4. Rohr HP, Bartsch G. Human benign prostatic hyperplasia: A Stromal disease? Urology 1980;16:625-633.
5. Lee C, Kozlowski JM, Grayhack JT. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 1997;31(2):131-138.
6. Cunha G, Battle E, Young P. Role of epithelial-mesenchymal interactions in the differentiation and spatial organization of visceral smooth muscle. Epith Cell Biol 1992;1:76-83.
7. Culig Z, Hobisch A, Cronauer VM, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28:392-405.
8. Giri D, Ropiquet F, Ittmann M. Alterations in expression of FGF2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999;5:1063-1071.
9. Giri D, Ropiquet F, Ittmann M. FGF2 is an autocrine and pararcrine prostatic growth factor expressed by prostatic stromal cells. J Cell Physiol 1999;180:53-60.
10. Ropiquet F, Giri D, Lamb D, Ittmann M. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 1999;162:595-599.
11. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner G. Phenotypic characterization of infiltrating leucocytes in BPH. Lab Invest 1992;66:96-107.
12. Steiner G, Gessl A, Kramer G, Schöllhammer A, Förster O, Marberger M. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 1994;151:480-484.
13. Griffiths K (Chairman), Akaza H, Eaton CL, El Etreby M, Habib F, Lee C, Partin AW, Coffey DS, Sciarra F, Steiner G, Tenniswood MP. Regulation of prostatic growth. In: Cockett AT, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy G, editors. The 2nd International Consultation on Benign Prostate Hyperplasia (BPH). Vol 2 Proceedings. Jersey: Scientific Communication International; 1993. 47-83.
14. Lee C, Cockett A, Cussenot o, Griffiths K, Isaacs W, Schalken J, Buttyan R, Prins G, Steiner GE. Regulation of prostatic growth. In: Chatelian C, Denis L, Foo KT, Khoury S, McConnell J, editors. 5th International Consultation on Benign Prostatic Hyperplasia (BPH). 2001.
15. Handisurya A, Steiner G, Stix U, Ecker RC, Pfaffeneder-Mantai S, Langer D, Kramer G, Memaran-Dadgar N, Marberger M. Differential expression of interleukin-15, a pro-inflammatory cytokine, and T-cell growth factor, and its receptor in human prostate. Prostate 2001;9999:1-12.
16. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee Ch, Marberger M. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002;52:43-58.
17. Steiner GE, Stix U, Handisurya A, Willeim M, Huitel A, Reithmayr F, Pnikl D, Ecker RC, Hrachowitz K, Kramer G, Lee C, Marberger M. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cyto-kine mRNA profile in prostatic tissue. Lab Invest 2003 [in press].
18. Rouvier E, Luciani M-F, Mattéi MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993;150:5445-5456.
19. Albrecht JC, Nicholas J, Biller D, Cameron KR, Biesinger B, Newman C, Wittmann S, Craxton MA, Coleman H, Fleckenstein B, Honess RW. Primary structure of the herpesvirus saimiri genome. J Virol 1992;66:5047-5058.
20. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ. Human IL-17: A novel cytokine derived from T-cells. J Immunol 1995;155:5483-5486.
21. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Sealand S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S. T cell interleukin-17 induces stromal cell to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-2603.
22. Albanesi CA, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: Synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 1999;162:494-502.
23. Jovanovic DV, Di Battista JA, Martell-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta, and TNF-alpha, by human macrophages. J Immunol 1998;160:3513-3521.
24. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem 1998;27:27467-27473.
25. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-177.
26. Lubberts E, Joosten LA, Van de Loo FA, van den Gersselaar LA, van den Berg WB. Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum 2000;43:1300-1306.
27. Miossec P. Are T cells in rheumatoid synovium aggressors or bystanders? Review. Curr Opin Rheumatol 2000;12:181-185.
28. Albanesi C, Scarponi C, Sebastiani S, Cavani A, Federici M, De Pita O, Puddu P, Girolomoni G. IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. J Immunol 2000;165:1395-1402.
29. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-649.
30. Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB, Thomson AW. Evidence for a role of IL-17 in alloimmunity: A novel IL-17 antagonist promotes heart graft survival. Transplant Proc 1999;31:93.
31. Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB, Thomson AW. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999;162:577-584.
32. Loong CC, Lin CY, Lui WY. Expression of interleukin-17 as a predictive parameter in acute renal allograft rejection. Transplant Proc 2000;32:1773.
33. Van Kooten C, Boonstra JG, Paape ME, Fossiez F, Banchereau J, Lebecque S, Bruijn JA, De Fijter JW, Van Es LA, Daha MR. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998;9:1526-1534.
34. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-104.
35. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R, Elias J, Chakir J. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001;108:430-438.
36. Li HL, Kostulas N, Huang YM, Xiao BG, van der Meide P, Kostulas V, Giedraitas V, Link H. IL-17 and IFN-gamma mRNA expression is increased in the brain and systemically after permanent middle cerebral artery occlusion in the rat. J Neuroimmunol 2001;116:5-14.
37. Fridman WH, Tartour E. Macrophage- and lymphocyte-produced Th1 and Th2 cytokines in the tumor microenvironment. Res Immunol 1998;149:651-653.
38. Tartour E, Fossiez F, Joyeux L, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V, Banchereau J, Fridman WH, Widjdenes J, Lebecque S, Sautes-Fridman C. Interleukin-17, a T-cell derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999;59:3698-3704.
39. Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S, Kamada M, Aono T. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Comm 2001;282:735-738.
40. Chaboud MF, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161:409-414.
41. Yao Z, Spriggs MK, Derry JM, Strockbine L, Park LS, VandenBos T, Zappone J, Painter SL, Armitage RJ. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 1997;9:794-800.
42. Haudenschild D, Moseley T, Rose L, Reddi H. Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing, and expression in prostate cancer. J Biol Chem 2002;277(6):4309-4316.
43. Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med 2000;191:1233-1239.
44. Franks LM. Benign prostatic hyperplasia: Gross and microscopic anatomy. In: Grayhack JT, Wilson JD, Scherbenske MJ, editors. Benign prostatic hyperplasia. Department of Health, Education, and Welfare (NIH) Publication. Washington DC: US Government Printing Office; 1976. p 76-1113.
45. Dohm G. Hyperplasie und sogenannte atypische Hyperplasie der Prostata. In: W Dörr, G Seifert, editors. Pathologie der männlichen Genitale. Berlin, Heidelberg, New York, London: Springer Verlag; 1991. p. 480.
46. Gleason DF. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992;23:273-279.
47. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: The Prostate. Philadelphia: Lea & Febiger; 1977. 171-198.
48. Luzza F, Parrello T, Monteleone G, Sebkova L, Romano M, Zarrilli R, Imeneo M, Pallone F. Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol 2000;165:5332-5337.
49. Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor α-induced synthesis of interleukins 1,6,8 in skin and synovial fibroblasts. Arthitis 2001;44:2176-2184.
50. Teranishi T, Hirano T, Arima N, Onoue K. Human helper T cell factor(s) (ThF). II. Induction of IgG production in B lymphoblastoid cell lines and identification of T cell-replacing factor (TRF)-like factor(s). J Immun 1982;128:1903-1908.
51. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986;324:73-76.
52. Van Damme J. The Cytokine Handbook, 2nd edition. In: Thomson A, editor. San Diego, CA: Academic Press Ltd.; 1994. 185.
53. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Path 2001;159:2159-2165.
54. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141-146.
55. Giri D, Ittmann M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Path 2001;159:139-147.
56. Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenisis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998;51:161-167.
57. Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL, Vessella RL, Ralph D. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 1999;53:139-147.